Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Tobira Therapeutics, Inc. | d931438d8k.htm |
| EX-10.1 - EX-10.1 - Tobira Therapeutics, Inc. | d931438dex101.htm |
| EX-10.2 - EX-10.2 - Tobira Therapeutics, Inc. | d931438dex102.htm |
Exhibit 16.1
| May 14, 2015
U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 |
Grant Thornton LLP 201 South College Street Suite 2500 Charlotte, NC 28244
T 704.632.3500 F 704.632.3500 www.GrantThornton.com |
| Re: | Tobira Therapeutics, Inc. (previously known as Regado Biosciences, Inc.) |
| File | No. 001-35953 |
Dear Sir or Madam:
We have read Item 4.01 of Form 8-K of Tobira Therapeutics, Inc. (previously known as Regado Biosciences, Inc.) dated May 14, 2015, and agree with the statements concerning our Firm contained therein.
Very truly yours,
/s/ GRANT THORNTON LLP